Lyell Immunopharma (NASDAQ:LYEL) Trading Up 4.9%

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price was up 4.9% during mid-day trading on Thursday . The company traded as high as $2.58 and last traded at $2.57. Approximately 233,721 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 963,725 shares. The stock had previously closed at $2.45.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, February 29th.

Lyell Immunopharma Trading Up 8.6 %

The stock has a market capitalization of $675.91 million, a price-to-earnings ratio of -2.84 and a beta of -0.56. The stock has a 50-day simple moving average of $2.19 and a 200 day simple moving average of $1.97.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. Sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors have recently bought and sold shares of the business. WuXi AppTec Co. Ltd. bought a new stake in Lyell Immunopharma in the fourth quarter valued at about $15,871,000. Vanguard Group Inc. increased its stake in shares of Lyell Immunopharma by 309.6% during the first quarter. Vanguard Group Inc. now owns 8,778,702 shares of the company's stock worth $44,332,000 after purchasing an additional 6,635,614 shares during the period. BlackRock Inc. grew its position in Lyell Immunopharma by 290.6% during the first quarter. BlackRock Inc. now owns 7,809,490 shares of the company's stock worth $39,438,000 after buying an additional 5,810,038 shares in the last quarter. State Street Corp grew its position in Lyell Immunopharma by 107.2% during the third quarter. State Street Corp now owns 5,379,838 shares of the company's stock worth $39,434,000 after buying an additional 2,783,919 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Lyell Immunopharma by 397.4% in the 1st quarter. Northern Trust Corp now owns 1,052,410 shares of the company's stock valued at $5,315,000 after purchasing an additional 840,833 shares in the last quarter. Institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.